Mural Oncology (MURA) said Tuesday it plans to explore strategic alternatives following a review of data from its phase 2 trial in melanoma and previously announced results from the phase 3 trial in platinum-resistant ovarian cancer.
The company said it is discontinuing all clinical development of nemvaleukin alfa and cutting its workforce by about 90%.
Mural said it has hired Lucid Capital Markets to serve as its financial adviser in connection with the exploration of strategic alternatives, adding that there was no assurance that the process will lead to any transaction.
The company said it has not received any approaches and was not in active discussions with any potential suitor.
Mural Oncology climbed by more than 95% in premarket trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。